@ErisBio joins the 2025 Memorial Sloan Kettering Therapeutics Accelerator—advancing a first-in-class oral therapy that blocks tumor immune evasion. This collaboration accelerates their mission to deliver new options for patients. #UtahLifeSciences 🔗 ow.ly/8aAB50WIwVn